about
Stereotactic Ablative Radiotherapy Versus Low Dose Rate Brachytherapy or External Beam Radiotherapy: Propensity Score Matched Analyses of Canadian Data.Randomized non-inferiority trial of Bicalutamide and Dutasteride versus LHRH agonists for prostate volume reduction prior to I-125 permanent implant brachytherapy for prostate cancer.The prostate cancer risk stratification (ProCaRS) project: recursive partitioning risk stratification analysis.RTOG 0518: randomized phase III trial to evaluate zoledronic acid for prevention of osteoporosis and associated fractures in prostate cancer patients.Image-Guided High-Dose-Rate (HDR) Boost Localization Using MRI/MR Spectroscopy: A Correlation Study with Biopsy.Development of ProCaRS Clinical Nomograms for Biochemical Failure-free Survival Following Either Low-Dose Rate Brachytherapy or Conventionally Fractionated External Beam Radiation Therapy for Localized Prostate CancerImage-guided high-dose-rate brachytherapy boost to the dominant intraprostatic lesion using multiparametric magnetic resonance imaging including spectroscopy: Results of a prospective study.Brachytherapy improves biochemical failure-free survival in low- and intermediate-risk prostate cancer compared with conventionally fractionated external beam radiation therapy: a propensity score matched analysis.An eight-year experience of HDR brachytherapy boost for localized prostate cancer: biopsy and PSA outcome.Multicenter Evaluation of Biochemical Relapse-Free Survival Outcomes for Intraoperatively Planned Prostate Brachytherapy Using an Automated Delivery System.Does Seed Migration Increase the Risk of Second Malignancies in Prostate Cancer Patients Treated With Iodine-125 Loose Seeds Brachytherapy?Validation of the French-Canadian version of the Expanded Prostate Cancer Index Composite (EPIC) in a French-Canadian population.Calcifications in low-dose rate prostate seed brachytherapy treatment: post-planning dosimetry and predictive factors.Quantifying the effect of seed orientation in postplanning dosimetry of low-dose-rate prostate brachytherapy.High-dose-rate brachytherapy boost for prostate cancer treatment: Different combinations of hypofractionated regimens and clinical outcomes.Does prostate volume has an impact on biochemical failure in patients with localized prostate cancer treated with HDR boost?Dose escalation to the dominant intraprostatic lesion defined by sextant biopsy in a permanent prostate I-125 implant: a prospective comparative toxicity analysis.Permanent prostate implant using high activity seeds and inverse planning with fast simulated annealing algorithm: A 12-year Canadian experience.The Prostate Cancer Risk Stratification Project: Database Construction and Risk Stratification Outcome AnalysisBypassing the learning curve in permanent seed implants using state-of-the-art technology[The impact of 3D image guided prostate brachytherapy on therapeutic ratio: the Quebec University Hospital experience][Clinical outcome of intermediate risk prostate cancer treated with iodine 125 monotherapy: The Hotel-Dieu of Quebec experience]Coupling I-125 permanent implant prostate brachytherapy Monte Carlo dose calculations with radiobiological modelsDuration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III TrialLarge-scale Retrospective Monte Carlo Dosimetric Study for Permanent Implant Prostate Brachytherapy
P50
Q31138973-71F7EDBC-486D-4C11-A647-9EEDB063F0DCQ34506507-157E2133-E95D-4D4B-855F-BC490CC79FC9Q35042913-151A427F-3C06-4234-BCC6-8C2EB77BE821Q37315868-44E490CD-9864-40E6-91F8-A850A69442F8Q37368378-A720BD8B-31F1-4B8D-B0B0-A35908B8A846Q38984178-0E6611A7-50BD-4598-AB9B-6CFF600B9689Q39288297-39FBA27A-963A-4C9B-9892-5250860B0E4DQ41571290-7A626A6C-1E25-4C9B-BA85-628CD95A48A2Q45248416-861E0BF5-A6A7-431D-9928-B73D95088338Q47954319-860C3CEC-F53F-4DD1-BC8A-4F1BA1754F56Q50084056-8CC03222-A82B-4605-9451-BE37FBED1FA6Q50141373-3E768A0F-366E-4A61-8006-15226861EEE0Q50599792-72F20FDC-B6DB-4094-9BDA-658CBB20E08CQ50630763-AD343943-3BEB-4152-8192-6328FC991173Q50922294-2F82CCEB-0577-45F7-9628-20B4B5B488E9Q51365792-F0312B0F-6BBF-4417-9DB6-5624811185B9Q51803428-EC8C7FCD-80E0-4BC2-A576-0C59C8C0049BQ51929528-DA75D4AA-75C9-4A0E-8462-A29044C76134Q59363457-4833DB52-46C9-4D10-9492-3B7E7C0F59CBQ80334708-437BA3DC-9E9D-490C-B0CD-94CE067104D6Q81587369-521F2074-1354-4E0C-96E4-A70676DAB896Q84107831-8C50AB1F-DD19-4B01-AE1A-5DD9D359F6FBQ87953661-BCE1D982-9296-440C-9AF2-050DD0D6D40AQ89447960-5283D44A-95CB-42D4-8685-A02133D7A42BQ89919326-CB3FA205-4F1E-4BF0-852E-C48D3AB06AAD
P50
description
Canadees arts
@nl
Canadian physician
@en
Canadian physician
@en-ca
Canadian physician
@en-gb
Kanada arst
@et
dochtúir Ceanadach
@ga
medic canadian
@ro
metge canadenc
@ca
mjek kanadez
@sq
médecin et chercheur canadien
@fr
name
Andre-Guy Martin
@ast
Andre-Guy Martin
@es
Andre-Guy Martin
@nl
Andre-Guy Martin
@sl
André-Guy Martin
@en
André-Guy Martin
@fr
André-Guy Martin
@ga
André-Guy Martin
@sq
type
label
Andre-Guy Martin
@ast
Andre-Guy Martin
@es
Andre-Guy Martin
@nl
Andre-Guy Martin
@sl
André-Guy Martin
@en
André-Guy Martin
@fr
André-Guy Martin
@ga
André-Guy Martin
@sq
prefLabel
Andre-Guy Martin
@ast
Andre-Guy Martin
@es
Andre-Guy Martin
@nl
Andre-Guy Martin
@sl
André-Guy Martin
@en
André-Guy Martin
@fr
André-Guy Martin
@ga
André-Guy Martin
@sq
P106
P1153
57199495487
P21
P27
P31
P496
0000-0003-4214-9148